Product Description: K-14585 is a peptide competitive PAR2 antagonist. K-14585 inhibits PAR2-dependent IL-8 production, NF-κB phosphorylation, and p38 signaling. K-14585 reduces SLIGKV (PAR2 agonist peptide)-induced Ca2+ mobilisation in primary human keratinocytes[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C51H56Cl2N8O4
References: [1]Goh FG, et al. Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling. Br J Pharmacol. 2009 Dec;158(7):1695-704./[2]Kanke T, et al. Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo. Br J Pharmacol. 2009 Sep;158(1):361-71. /[3]Sevigny LM, et al. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8491-6.
CAS Number: 880546-17-8
Molecular Weight: 915.95
Research Area: Inflammation/Immunology
Target: NF-κB;p38 MAPK;Protease Activated Receptor (PAR)